Marimed initiated with an Outperform at Noble Capital

Noble Capital analyst Joe Gomes initiated coverage of Marimed (MRMD) with an Outperform rating and 25c price target With operations in six states, MariMed is a vertically integrated seed-to-sale cannabis provider and “cannabis brand powerhouse” with leading market shares in current markets and significant expansion potential both within existing markets and new markets, the analyst tells investors.